By Chris Wack
Cellectar Biosciences shares were up 18% to $2.15 after the company entered into a securities purchase agreement with certain institutional investors for a private placement financing.
The transactions are expected to result in gross proceeds of up to $102.9 million, including an initial funding of $24.5 million priced at $1.82…
Read the full article here
